TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07099898: Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), Compared With Topotecan in Participants With Relapsed Small Cell Lung Cancer (SCLC)

Sponsor: GlaxoSmithKline · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 420 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$787,248

Rescue Site Savings

+$524,832

Unlock Full NCT07099898 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07099898 Rescue Dossier →